Shilpa Medicare Ltd Q3 FY26 – ₹411 Cr Revenue, 28% YoY Growth, EBITDA Margin Near 28%: Oncology APIs, Biosimilars & The Long Road Back to Respectability
1. At a Glance – The “Wait, This Stock Still Exists?” Moment
Shilpa Medicare is one of those companies that never fully disappeared, but also never fully arrived. As of early Feb 2026, the stock is chilling around ₹316 with a market cap of roughly ₹6,178 crore—down meaningfully from its highs, but very much alive. Over the last 3 months, returns are negative (~-14%), and over 6 months even worse (~-28%). Ouch. But zoom into the latest numbers and suddenly the tone changes.
Q3 FY26 revenue clocked in at ~₹411 crore, up ~28% YoY, with EBITDA of ~₹115 crore and operating margins flirting with 28–29%. PAT for the quarter was ~₹45 crore. That’s not “struggling midcap pharma” territory—that’s “excuse me, what changed?” territory.
Yet valuation isn’t cheap-cheap. At ~35x trailing earnings and ~2.5x book, the market is clearly pricing in hope—hope that APIs stabilise, formulations scale, biosimilars stop being PowerPoint slides, and the CDMO story finally pays rent. ROCE (~8%) and ROE (~4%) are still unimpressive, debt sits around ₹590+ crore, and working capital days are… let’s just say not something you’d show your parents.
So what’s going on here? Is this a genuine turnaround or just another pharma false dawn? Let’s open the files.
2. Introduction – A Veteran Pharma Player with a Complicated Past
Founded in 1987, Shilpa Medicare has been around long enough to see multiple pharma cycles: API booms, USFDA scares, China dumping, oncology hype, biosimilar dreams, and investor patience slowly evaporating. For years, Shilpa was that oncology API company—solid chemistry skills, wide DMF base, global regulatory approvals, but frustratingly inconsistent financial performance.
The last decade reads like a mixed report card. Revenues grew, then stagnated. Margins collapsed post-FY19. ROCE slid from high teens to low single digits. Working capital ballooned. Debt increased. And shareholders waited… and waited.
But somewhere around FY24–FY25, the script started changing. APIs stopped bleeding. Formulations began contributing meaningfully. Oral dissolving films (ODF) and transdermal patches moved from “R&D curiosity” to actual approvals. Biosimilars and biologics started generating CDMO revenues instead of just burning cash. And suddenly, quarterly PAT went from single digits to ₹40–50 crore.
The market is now asking: is this the start of a multi-year recovery cycle, or just a couple of good quarters stitched together by accounting luck and one-off launches?
3. Business Model – WTF Do They Even Do?
Let’s simplify Shilpa Medicare without lying.
Core buckets:
APIs & Intermediates (≈68% of 9M FY24 revenue) This is the OG business—oncology APIs supplied across regulated and semi-regulated markets (US, EU, Japan, Korea, LATAM, etc.). Over 30 oncology molecules, multiple DMFs, and facilities approved by USFDA, EU, PMDA Japan, TGA Australia… basically a regulatory passport collection.
This is where Shilpa is trying to climb the value chain—especially in niche delivery systems like ODFs and patches, where competition is lower and pricing power is better.
Biologics & Biosimilars (via Shilpa Biologics Pvt Ltd) The long-gestation bet. 11 biosimilars + 1 NBE in pipeline, CDMO contracts signed, and early revenues finally trickling in. High risk, high capex, high reward… someday.
CDMO / CRAMS Both small molecule and biologics CDMO. Recent wins from Japan and Spain hint that the chemistry credibility still exists.
In short: Shilpa wants to be a specialty pharma platform, not just an API vendor. The ambition is clear. Execution… historically patchy.
4. Financials Overview – Numbers Don’t Lie, But They Do Smirk
